Placebo + LEBRIKIZUMAB for eczema

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 21 Feb 2023: Trial registered, NCT05735483
  2. 9 Mar 2023: Trial started, NCT05735483

The trials

NCT05735483: A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

State
Under way
Phase
Phase 3
People
338 planned
Started
9 Mar 2023
Primary completion
Dec 2027
Arms
Lebrikizumab, Lebrikizumab - Optional Extension Period (OEP)
Results
None posted
  1. 21 Feb 2023: Trial registered
  2. 9 Mar 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.